Prakiraan rega marang bathi: Codexis, Inc. (CDXS)

Market fluctuations in Codexis, Inc. (CDXS) share prices reflect the P/E ratio dynamics, which currently stands at 0.00. Codexis, Inc. specializes in the development and implementation of advanced medical solutions based on genetic technologies. The business relies on exclusive patents in protein engineering, which guarantees sustainable pricing power. Due to its autonomy from global economic crises, the sector remains a reliable defensive asset for capital protection.

CDXS - Kapitalisasi marang proyeksi bathi codexis.com ing rentang 04.07.2022 - 10.11.2026

Rincian metrik keuangan lan pasar Codexis Bio (CDXS)

- kuotasi lan prakiraan analis:

Rega saham Codexis, Inc.|CDXS - Rata-rata rega prakiraan

- indikator kapitalisasi bursa perusahaan:

Biji pasar Codexis Inc|CDXS - Nilai Bisnis

- statistik nilai buku emiten:

Nilai Buku saben Saham Codexis, Inc.|CDXS - Pambiji Buku Bisnis|Rasio Nilai Pasar marang Nilai Buku codexis.com|CDXS - Gunggung Aset Perusahaan

- rincian struktur utang lan likuiditas bisnis:

Rasio Total Utang marang Ekuitas Codexis, Inc.|CDXS - Koefisien utang jangka dawa marang modal|Utang jangka cendhak marang modal Codexis, Inc.|CDXS - Gunggung kewajiban utang perusahaan|Rasio utang marang kapitalisasi buku Codexis Inc|CDXS - Tanggungan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Codexis, Inc.|Indikator likuiditas cepet codexis.com

- statistik bathi lan rasio pasar:

CDXS - Asil keuangan resik|Proyeksi bathi mangsa ngarep Codexis, Inc.|CDXS - Koefisien rega marang bathi|Pangali Forward P/E Codexis, Inc.|CDXS - Rasio P/E diaturake wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Codexis Inc|CDXS - Bathi operasional sadurunge amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Codexis, Inc.|CDXS - Bathi resik saben saham sajrone patang kuartal pungkasan|Wutah bathi EPS kuartalan codexis.com|CDXS - Wutah bathi saben saham ing taun iki|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Codexis, Inc.

Analisis dhasar perusahaan:CDXS Codexis

Codexis, Inc. (CDXS) is transforming its business model by shifting toward the licensing of high-margin nucleic acid synthesis technologies. The business's forward P/E multiple reflects the dynamics of market expectations regarding future earnings through a daily recalculation of value. Investors utilize this indicator to identify price anomalies and assess risks. Stable values on the curve may signal either undervaluation or stagnation. Analyzing the business's forward P/E multiple allows for an assessment of the effectiveness of the current strategic pivot.

Karo sapa Codexis, Inc. saingan